Clinical Scorecard: Utilizing Artificial Intelligence to Differentiate Between Multisystem Inflammatory Syndrome in Children and Endemic Typhus: A Comparative Study of MIS-C and Typhus (AI-MET)

At a Glance

Key Highlights

• MIS-C and endemic typhus share overlapping clinical and laboratory features including fever, rash, abdominal pain, thrombocytopenia, transaminitis, and systemic inflammation.
• AI-MET, a two-phase artificial intelligence decision support system, uses 17 to 30 rapidly available clinical and laboratory features to distinguish MIS-C from typhus with near-perfect accuracy.
• Early differentiation is critical as treatments diverge: immunomodulation for MIS-C and tetracycline antibiotics for typhus, with early therapy improving outcomes.

Guideline-Based Recommendations

Diagnosis

• Use CDC 2020 criteria for MIS-C diagnosis including positive SARS-CoV-2 serology and multisystem inflammation.
• Confirm typhus diagnosis with Rickettsia typhi IgM serology, recognizing delayed turnaround times limit immediate clinical utility.
• Employ AI-MET decision support system to differentiate MIS-C from typhus using clinical and laboratory features available within 6 hours.

Management

• Initiate immunomodulatory therapy promptly for MIS-C patients.
• Start tetracycline-class antibiotics early for patients diagnosed with endemic typhus.
• Recognize that severe typhus may require intensive care similar to MIS-C presentations.

Monitoring & Follow-up

• Monitor cardiac involvement including myocarditis and coronary artery changes in MIS-C.
• Observe for inflammatory cardiac disease and systemic complications in severe typhus cases.
• Track laboratory markers such as C-reactive protein, platelet counts, liver enzymes, and sodium levels to assess disease progression.

Risks

• Delayed or incorrect diagnosis may lead to inappropriate treatment and worse outcomes.
• Overlap in clinical features can cause misclassification without decision support tools.
• Severe disease in both conditions can lead to shock and require intensive care.

Patient & Prescribing Data

Children hospitalized with febrile illness suspected of MIS-C or endemic typhus in endemic regions.

Early initiation of disease-specific therapy guided by AI-MET classification improves clinical outcomes; immunomodulation for MIS-C and tetracycline antibiotics for typhus.

Clinical Best Practices

• Collect comprehensive clinical and laboratory data within 6 hours of presentation for febrile children with systemic inflammation.
• Utilize AI-based decision support systems such as AI-MET to improve diagnostic accuracy between MIS-C and typhus.
• Recognize epidemiologic context and maintain high suspicion for both conditions in endemic areas.
• Ensure rapid initiation of appropriate therapy based on accurate diagnosis to reduce morbidity.
• Monitor cardiac and systemic inflammatory markers closely during treatment.

References

• CDC MIS-C Case Definition
• World Health Organization MIS-C Surveillance
• AI-MET Study on MIS-C and Typhus Differentiation